Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players

Area of Science:

• Oncology
• Pharmacology

Background:

• Breast cancer is a leading global health concern for women, presenting significant mortality and morbidity.
• Current treatments, including selective estrogen receptor modulators (SERMs) like tamoxifen and raloxifene, face limitations such as drug resistance and adverse effects like uterine cancer and thromboembolic events.

Purpose of the Study:

• To review current breast cancer treatment strategies and identify areas for improvement.
• To highlight the need for novel therapeutic agents, enhanced molecular models, and improved biomarkers for breast cancer management.

Main Methods:

• Literature review of existing breast cancer therapies, including SERMs and aromatase inhibitors (AIs).
• Discussion of treatment combinations, such as AIs with tamoxifen.
• Exploration of ongoing research and clinical trial needs.

Main Results:

• Tamoxifen resistance and adverse effects limit the long-term efficacy of current treatments.
• Aromatase inhibitors offer an alternative, and combinations with tamoxifen may be beneficial.
• Ongoing research focuses on developing new agents with improved efficacy and reduced side effects.

Conclusions:

• There is a critical need for advanced molecular models to identify high-risk populations.
• Development of novel therapeutic agents with superior benefit-risk profiles is essential.
• Improved biomarkers are required for more effective breast cancer treatment and patient stratification.